Table 1. Patient demographics and clinical characteristics.
| No. of patients | % | Median (range) | |
|---|---|---|---|
| 23 | 100 | ||
| Age | 58 (31-67) | ||
| Sex Female Male |
13 10 |
57 43 |
|
| Histological subtype FL MZL MCL |
17 1 5 |
74 4 22 |
|
| Stage of disease at first diagnosis II III/IV |
2 21 |
9 91 |
|
| Bulky disease | 9 | 39 | |
| Bone marrow involvement | 5 | 22 | |
| LDH normal elevated not available |
15 5 3 |
65 22 13 |
|
| Prior Rituximab | 12 | 52 | |
| No. of previous regimens | 3 (1-11) | ||
| Duration of response after last standard therapy (months) | 7 (1-57) | ||
| Pre-RIT status PR SD PD |
11 5 7 |
48 22 30 |
|
| FLIPI 0-1 2 >2 |
5 7 2 |
28 39 11 |
|
| IPI >1 ≤ 1 |
12 11 |
52 48 |
FL, follicular lymphoma; MZL, marginal zone lymphoma; MCL, mantle cell lymphoma; LDH, lactate dehydrogenase; PR, partial response; CR, complete response; SD stable disease; PD, progressive disease; FLIPI, follicular lymphoma international prognostic index; IPI, international prognostic index.